Andrew Harrow is a partner in the firm’s Life Sciences group. Mr. Harrow advises on a wide range of UK and cross-border transactions including joint ventures, mergers and acquisitions, reorganisations, initial public offerings and fundraisings for listed and private companies internationally as well as general corporate and capital market matters. He has a particular interest in transactions in the life sciences, healthcare and technology sectors.

Mr. Harrow has been noted for his private equity work in The Legal 500 UK, 2016 and recommended in The Legal 500 UK in 2015, 2017 and 2018 in the field of pharmaceuticals and biotechnology; he was also described as “brilliant” with respect to M&A work.

Prior to joining Goodwin in 2018, Mr. Harrow was a partner at Dechert LLP.






Life Sciences Transactions

  • Enterprise Therapeutics Ltd on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments. 
  • Inflazome Limited and its shareholders on the sale of 100% of its equity share capital to Roche for total initial consideration of €380 million.
  • Staten Biotechnology B.V. on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidemia, by way of an option to acquire structure.
  • Orchard Therapeutics plc in its $225 million initial public offering on NASDAQ.
  • Gadeta B.V. on its strategic collaboration with Kite Pharma Inc. to develop novel gamma delta T cell receptors therapies in various cancers together with the grant to Kite of an exclusive option to acquire Gadeta.
  • Prexton Therapeutics B.V. and its selling shareholders in its sale to global pharmaceutical company H. Lundbeck A/S for up to €905 million.*
  • The shareholders of Stat-Dx, a privately owned Spanish diagnostics company, on its sale to QIAGEN N.V., for $191 million (including milestones).*
  • The shareholders of Ziarco Group Limited in connection with the sale of the company to Novartis.*
  • The shareholders of XO1 Limited (including Index Ventures) on the sale of XO1 Limited to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.*
  • The shareholders of biopharmaceutical company Covagen AG in relation to the sale of Covagen to the Janssen Pharmaceutical Companies of Johnson & Johnson.*
  • An international investment manager in connection with its participation in BioNTech AG’s $270 million Series A financing.*
  • ProFibrix B.V. in connection with its sale to NASDAQ-listed The Medicines Company.*
  • Auven Therapeutics on its acquisition of Spirogen and the subsequent sale of Spirogen to Medimmune/AstraZeneca.*
  • Nomura Code Securities in relation to Silence Therapeutic plc’s merger with Intradigm Corporation and its placing and offer for a subscription of shares.*

Other Transactions

  • KaNDy Therapeutics on its sale to Bayer for $425 million upfront with up to $450 million in development milestone payments and triple digit millions in commercial milestones 
  • Index Ventures and Accel in relation to the IPO of Funding Circle Holdings plc on the London Stock Exchange.
  • Capital Z Partners LP in connection with its acquisition of Prestige Insurance Holdings Limited (the largest privately owned insurance broker and managing general agent in Northern Ireland) and owner of Northern Ireland’s leading insurance broker Abbey Insurance.
  • Index Ventures, Greylock Partners, Redpoint Ventures, SM Trust and Vitruvian Partners (the majority shareholders of leading online takeaway service in relation to the IPO of on the London Stock Exchange’s High Growth Segment and their subsequent sales of additional shares in JustEat in several tranches by way of various accelerated bookbuild processes.*
  • AIM-listed ACM Shipping Group plc in connection with its £150 million recommended merger with London Stock Exchange Main Market-listed Braemar Shipping Services plc, effected by way of scheme of arrangement.*
  • The Mohamed Al Fayed family trust in connection with the sale of Fulham Football Club to Shahid Khan, the CEO of Flex-N-Gate Group and owner of the NFL team, the Jacksonville Jaguars.*
  • Tilda Limited, a leading Basmati and specialty rice products company, and its shareholders on the sale of Tilda to NASDAQ-listed Hain Celestial Group, Inc.*
  • Kofax Limited, a leading provider of smart process applications for the business-critical First Mile of customer interactions, on its restructuring proposals creating a new holding company incorporated in Bermuda implemented by way of scheme of arrangement together with new premium listings on the Main Market of the London Stock Exchange and the NASDAQ Global Select Market.*
  • NYSE-listed FMC Corporation in its acquisition of Phytone Ltd., a natural colours producer based in the United Kingdom.*
  • PhotoBox, Europe’s largest online photo processing service, on its £120 million acquisition of Limited and related group reorganisation, debt and equity financing.*
  • Liberty plc, the iconic Regent Street retail business, and its majority shareholder MWB Group Holdings plc in connection with its £71.5 million takeover by BlueGem Capital Partners LLP.*
  • The Republic of Serbia and Nomura, as financial advisor, on the privatisation of Vojvodjanska Banka Novi Sad and its €385 million sale to The National Bank of Greece.*
  • The Crown Estate in connection with its £680 million joint venture with British Land Co. plc.*
  • A NYSE-listed international conglomerate in connection with the acquisitions of various businesses in the United Kingdom.*
  • Altima Partners, as sponsor, and Campos Verdes Ltd. on its $613.2 million business combination with El Tejar SAACEI to form El Tejar Limited, one of the leading agribusinesses in Latin America.*
  • Capital Z Partners LP in connection with its acquisition from 3i plc of its interest in Jelf Group plc and associated subscription for new shares in Jelf Group plc.*
  • Spark Advisory Partners Limited, as nominated adviser, and WH Ireland Limited and Whitman Howard Limited, as joint brokers, on the admission to trading on AIM of IMIMobile plc, a leading global technology company.*
  • Shore Capital as nominated adviser and broker to SafeCharge International Group Limited, an international provider of payments services, risk management and IT solutions for online businesses, on its US$400 million (c.£242.6 million) IPO on AIM.*
  • Shore Capital & Corporate Limited and Shore Capital Stockbrokers Limited on an equity fundraising and debt restructuring by AIM-listed Styles & Wood plc.*

* Denotes experience prior to joining Goodwin.

In The News









Legal Practice Course, 1999
Nottingham Law School
Post-Graduate Diploma in Law, 1998
Nottingham Law School
B.A., Geography
St. John's College, Oxford



Solicitor of the Senior Courts of England and Wales
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique